ACELYRIN Inc (SLRN) News

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm PR Newswire NEW YORK, Feb. 10...

Form 425 - Prospectuses and communications, business combinations

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. PR Newswire NEW YORK, Feb. 7, 2025 NEW YORK, Feb. 7, 2025...

Form 8-K - Current report

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate...

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma...

Form 8-K - Current report

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve...

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report